Subcutaneous vascular assemblies for improving blood flow and related devices and methods

Information

  • Patent Grant
  • 11331458
  • Patent Number
    11,331,458
  • Date Filed
    Tuesday, October 30, 2018
    6 years ago
  • Date Issued
    Tuesday, May 17, 2022
    2 years ago
Abstract
Reinforcing sleeves for medical device lumens are disclosed. In some embodiments reinforcing sleeves may provide resistance to crushing, kinking, or other deformation of the lumen. Reinforcing sleeves within the scope of this disclosure may be displaceable along an outer diameter of a reinforced lumen. Some reinforcing sleeves within the scope of this disclosure comprise metal alloys.
Description
TECHNICAL FIELD

The present disclosure relates generally to the field of medical devices. More particularly, some embodiments relate to medical assemblies and devices for improving blood flow to regions of a patient's body.





BRIEF DESCRIPTION OF THE DRAWINGS

The written disclosure herein describes illustrative embodiments that are non-limiting and non-exhaustive. Reference is made to certain of such illustrative embodiments that are depicted in the figures, in which:



FIG. 1 is a perspective view of a medical device, according to an embodiment.



FIG. 2 is cross-sectional side view of the medical device of FIG. 1.



FIG. 3 is a perspective view of a reinforcing sleeve of the medical device of FIG. 1, according to an embodiment.



FIG. 4 is a side view of the medical device of FIG. 1 in a bent configuration.



FIG. 5 is a side view of the medical device of FIG. 1 with a push force being applied to the reinforcing sleeve.



FIG. 6 is a side view of the medical device of FIG. 1 with a pull force being applied to the reinforcing sleeve.



FIG. 7 is a side view of the medical device of FIG. 1 with a plurality of reinforcing sleeves.



FIG. 8 is a posterior view of a leg of a patient into whom the medical device of FIG. 1 has been implanted.



FIG. 9 is a perspective view of a medical device, according to an embodiment.



FIG. 10 is a cross-sectional side view of the medical device of FIG. 9.



FIG. 11 is a perspective view of adjusting the length of a reinforcing sleeve of the medical device of FIG. 9.



FIG. 12 is a perspective of the medical device of FIG. 9 with attachable end caps according to an embodiment.



FIG. 13 is a side view of an embodiment of a medical device with a plurality of reinforcing sleeves.





DETAILED DESCRIPTION

Many individuals suffer from insufficient blood flow to regions (e.g., peripheral regions) of their body. For example, some individuals suffering from peripheral artery disease experience narrowing of one or more peripheral arteries (e.g., a superficial femoral artery) to their leg(s) or arm(s). Such narrowing of the arteries may reduce blood flow to one or more peripheral regions. Insufficient blood flow to the extremities of the body can lead to critical limb ischemia, gangrene, and/or amputation. Diabetes is known to increase the risk of peripheral artery disease.


Insufficient blood flow to peripheral regions of a body may result from other causes as well. For example, in addition to atherosclerosis in peripheral arteries, blood flow to a peripheral region may be impeded by some other blockage. In other cases, a portion of an artery may be punctured or weakened, thereby rendering the artery (or a portion of the artery) unsuitable for providing long-term blood flow to a peripheral region.


Embodiments described herein may be used to form a non-natural flow path that improves blood flow to regions of a patient. For example, in some embodiments, a medical device that includes a first graft portion, a second graft portion, and a catheter portion that is coupled to and disposed between the first graft portion and the second graft portion may be inserted into a patient such that the first graft portion is coupled to the vasculature at a first location that is above the knee of a patient, and the second graft portion is coupled to the vasculature at a second location that is below the knee of the patient. The new flow path that is established between the first location and the second location may improve blood flow to a region (e.g., the lower leg or foot) of the patient.


The components described herein may additionally or alternatively be used to establish other non-natural flow paths within a patient. In some embodiments, both ends of the non-natural flow path are coupled to vasculature of the patient. In other embodiments, only one end of the non-natural flow path is coupled to vasculature of the patient. In some embodiments, the non-natural flow path is disposed within the torso region of the patient. In other embodiments, the non-natural flow path is disposed below the waist. In some embodiments, the non-natural flow path extends from above the waist to below the waist. In some embodiments, the non-natural flow path traverses the knee (i.e., connects the upper leg with the lower leg). In some embodiments, one end of the non-natural flow path empties directly into a chamber of the heart. Other suitable locations for non-natural flow paths formed by medical devices described herein are possible and within the scope of this disclosure.


The components of the embodiments as generally described and illustrated in the figures herein can be arranged and designed in a wide variety of different configurations. Thus, the following more detailed description of various embodiments, as represented in the figures, is not intended to limit the scope of the present disclosure, but is merely representative of various embodiments. While various aspects of the embodiments are presented in drawings, the drawings are not necessarily drawn to scale unless specifically indicated.


The phrase “coupled to” is broad enough to refer to any suitable coupling or other form of interaction between two or more entities. Thus, two components may be coupled to each other even though they are not in direct contact with each other. For example, two components may be coupled to one another through an intermediate component. The phrase “attached to” refers to interaction between two or more entities which are in direct contact with each other and/or are separated from each other only by a fastener of any suitable variety (e.g., an adhesive).


As used herein, the term “crush force” refers to the magnitude of a two-dimensional force (e.g., pinch force) that is applied perpendicular to the longitudinal axis of a tube that causes deformation of the tube from an unconstrained state to a constrained state in which the distance between opposite sides of the tube is three-quarters of the distance between opposite sides of the tube when the tube is unconstrained. As used herein, the term “hoop force” refers to the magnitude of a force that is uniformly applied around a circumference of a tube to compress the tube to three-quarters of its initial diameter. A “porous tube” is considered to be porous even if the porous tubular structure is coated, disposed between, or embedded within a non-porous polymer. For example, a tubular wire structure that includes openings between adjacent elements of wire is porous even if the tubular wire structure is coated, disposed between, or embedded within a non-porous polymer.



FIGS. 1-7 provide alternative views of a medical device 100 (or a portion thereof) that establishes a non-natural flow path for improving blood flow to a region of a patient, such as a lower leg, a foot, an arm, or a hand. More specifically, FIG. 1 provides a perspective view of medical device 100. FIG. 2 provides a cross-sectional view of medical device 100. FIG. 3 provides a perspective view of a reinforcing sleeve 120. FIG. 4 provides a perspective view of medical device 100 with reinforcing sleeve 120 in a bent configuration. FIG. 5 provides a side view of medical device 100 with a push force being applied to reinforcing sleeve 120. FIG. 6 illustrates a side view of medical device 100 with a pull force being applied to reinforcing sleeve 120. FIG. 7 illustrates medical device 100 with multiple reinforcing sleeves 120.


As shown in FIGS. 1-7, medical device 100 includes a lumen 110 that has a tubular structure and a reinforcing sleeve 120. A first end 112 of lumen 110 is configured to couple by anastomosis to a first portion of a vasculature of a patient, such as a vein or artery, and a second end 114 of lumen 110 is configured to couple by anastomosis to a second portion of the vasculature of the patient. Lumen 110 provides a flow path 116 from the first portion of the vasculature to the second portion of the vasculature to bypass a narrowed, obstructed, damaged, and/or diseased portion of the vasculature. Lumen 110 may have an inner lining 118 that provides a continuous and smooth luminal surface for blood flow. Such a luminal surface may reduce blood turbulence and clotting in lumen 110. In some embodiments, inner lining 118 is made of a porous material. In some embodiments, inner lining 118 of lumen 110 is configured to permit tissue ingrowth. In some embodiments, inner lining 118 of lumen 110 is configured to provide an antithrombotic surface and/or an anti-inflammatory surface.


Lumen 110 may be synthetic, biologic, or a native vessel. In some embodiments, lumen 110 may be formed from a relatively flexible material. In addition, lumen 110 may be formed from a material that is suitable for anastomosis to a vein or artery of a patient. Suitable materials include, but are not limited to Polytetrafluoroethylene (PTFE), silicone, polyurethane, fluoroelastomers, fluorosilicone, PEBAX, and the like.


In some embodiments, lumen 110 may comprise multiple layers. For example, lumen 110 may have an inner layer formed from a polymer, such as porous PTFE. More specifically, the inner layer may be formed from expanded PTFE or fibrous PTFE. In embodiments that use fibrous PTFE, the fibrous PTFE may be formed by rotation of a spinneret (i.e., rotational spun PTFE) and/or by subjecting a solution or dispersion comprising PTFE to an electric field (i.e., electrospun PTFE).


Lumen 110 may also include an outer (i.e., abluminal) layer. Like the inner layer, the outer layer may be formed from a polymer such as porous PTFE. In some embodiments, the outer layer is configured to permit tissue ingrowth. In some embodiments, the outer layer is identical in composition to the inner layer. In other embodiments, the outer layer and the inner layer differ in composition.


In some embodiments, lumen 110 may include an intervening layer that is disposed between the inner layer and the outer layer. For example, in some embodiments, the intervening layer comprises one or more of silicone, fluorinated ethylene propylene (FEP), and polyether block amide (e.g., PEBAX). In some embodiments, the intervening layer may be an elastomeric material, such as silicone, that allows for resealing of lumen 110 after puncture. In other words, in some embodiments, at least a portion of lumen 110 may be pierced by a needle or other sharp object. Once the needle or other sharp object is retracted from lumen 110, the intervening layer may reseal about the aperture formed by the inserted needle or sharp object, thereby preventing the leakage of blood or other fluid across a wall of lumen 110. Such resealability may permit early cannulation of lumen 110 (e.g., cannulation within one week of implantation). In some embodiments, the silicone layer may be extruded silicone, and form an extruded silicone tube. Extruded silicone may have residual stresses that increase the resealability of the intervening layer. In some embodiments, the silicone layer may be the outer layer of lumen 110. In some embodiments, the silicone layer may be the inner layer of the lumen 110. The elastomeric material may provide increased durability after cannulation resulting in increased life and a smaller biological response. The self-sealing nature of the layer may provide several benefits, such as, reduced thrombus production, increased mechanical integrity of lumen 110, and reduced flow disturbances within lumen 110.


The length of lumen 110 is dependent on the situation in which lumen 110 is used to create a non-natural flow path. As discussed previously, lumen 110 enables a bypass of a narrowed, obstructed, damaged, and/or diseased portion of the patient's vasculature. The length of lumen 110 may be determined by (1) the desired location for placement in the patient and/or (2) the particular anatomy of the patient. The length of lumen 110 may be customizable, and a medical professional may trim the length of lumen 110 to meet the specific situation of a particular patient.



FIG. 3 illustrates reinforcing sleeve 120. Reinforcing sleeve 120 is configured to slide along lumen 110 to enable a medical professional to position reinforcing sleeve 120 to a desired location to reinforce and strengthen lumen 110. Reinforcing sleeve 120 may strengthen various types of lumens 110, such as synthetic, biologic, and native vessels, as previously discussed. The length of lumen 110 may vary depending on the situation of the patient. Since lumen 110 may be made from a relative flexible material, lumen 110 may be susceptible to damage or tearing. Reinforcing sleeve 120 is designed to increase the hoop strength, crush resistance, and longitudinal strength of lumen 110. In some embodiments, reinforcing sleeve 120 has a crush force that is greater than lumen 110. The high crush force of reinforcing sleeve 120 may prevent or reduce the risk of collapse of lumen 110. In some embodiments, reinforcing sleeve 120 has a hoop force that is greater than lumen 110. Due to the relatively high crush force and/or hoop force of reinforcing sleeve 120, reinforcing sleeve 120 may be suited for positioning within a patient where strength and/or crush resistance is warranted. For example, reinforcing sleeve 120 may be designed to be positioned adjacent to bones or ligaments that might cause the collapse of lumen 110, which is formed from weaker materials. In some embodiments, reinforcing sleeve 120 is positioned adjacent relatively sharp anatomy or in locations in which there is significant movement, such as joints like knees, ankles, hips, wrists, elbows, etc. In some embodiments, reinforcing sleeve 120 is designed to traverse a relatively sharp bend without kinking. The reinforcing sleeve 120 may additionally or alternatively be designed to be positioned at a relatively exposed location that is likely to be subjected to compression forces with some frequency. In other words, reinforcing sleeve 120 may be positioned along lumen 110 within the patient at a location where strength is warranted and/or along the portion of the flow path that is most likely to fail or necessitate replacement.


Reinforcing sleeve 120 includes a reinforcing structure 122 that is designed to increase the hoop strength, crush resistance, and longitudinal strength of lumen 110. Reinforcing structure 122 may be formed by braiding, as illustrated in FIG. 3. The braided structure may provide a crush force greater than the crush force of lumen 110.


Reinforcing structure 122 may comprise and/or consist of a metal alloy that is inert in the human body. For example, in some embodiments, reinforcing structure 122 comprises and/or consists of a nickel-titanium alloy, such as nitinol.


Reinforcing sleeve 120 may further include end caps 124 and 126 to prevent fraying of reinforcing structure 122. End caps 124 and 126 may also provide a location for the medical professional to grip reinforcing sleeve 120 and to slide reinforcing sleeve 120 along lumen 110. End caps 124 and 126 may comprise an inert material in a human body, such as silicone, PTFE, etc.



FIG. 4 illustrates medical device 100 and reinforcing sleeve 120 in a bent configuration. In some situations, medical device 100 is bent in order to create a flow path from a first portion of the vasculature to a second portion of the vasculature. In these situations, there is the possibility that lumen 110 may become kinked and substantially limit or decrease the flow through lumen 110. In these situations, reinforcing sleeve 120 may be positioned at the bending location to reinforce the bend and also prevent kinking of lumen 110. Reinforcing sleeve 120 may bend up to at least 180 degrees, as illustrated in FIG. 4, and prevent kinking of lumen 110. This may be beneficial if lumen 110 needs to make a sharp turn in order to create a non-natural flow path.


As discussed previously, reinforcing sleeve 120 may be placed on lumen 110 and the position of reinforcing sleeve 120 may be adjusted by sliding reinforcing sleeve 120 relative to lumen 110. To slide reinforcing sleeve 120 along lumen 110, a push force may be applied to reinforcing sleeve 120. FIG. 5 illustrates a force F1 being applied to lumen 110 in a first direction and a force F2 applied to end cap 124 closest to force F1 in a second direction, resulting in a net push force on the reinforcing sleeve 120. Accordingly, when the push force is applied to reinforcing sleeve 120, the medical professional may slide reinforcing sleeve 120 relative to lumen 110 to a predetermined location. The predetermined location may be determined by the medical professional to reinforce lumen 110 at specific locations where lumen 110 may be susceptible to damage or tearing.


Alternatively, if a pull force is applied to reinforcing sleeve 120, reinforcing sleeve 120 locks up and secures to lumen 110. For example, if a force F3 is applied to end cap 126 in the second direction farthest from force F1 applied in the first direction, as illustrated in FIG. 6 and resulting in a net pull force on the reinforcing sleeve 120, the reinforcing sleeve 120 locks to lumen 110. The structure of reinforcing sleeve 120 may determine how reinforcing sleeve 120 locks or secures to lumen 110. The structure of braided reinforcing structure 122 of reinforcing sleeve 120 clamps to lumen 110 when a pull force is applied to reinforcing sleeve 120. The braids of reinforcing structure 122 tighten and clamp against lumen 110 to lock reinforcing sleeve 120 in place.


Reinforcing sleeve 120 may be secured to lumen 110 by a number of different methods. After reinforcing sleeve 120 is positioned by the medical professional along lumen 110 to the predetermined position, the medical professional may secure or lock reinforcing sleeve 120 to lumen 110. For example, reinforcing sleeve 120 may be secured to lumen 110 by adhesives, fasteners, and the like. Alternately, reinforcing sleeve 120 may be simply be placed in the predetermined position and secured in place by the braids of reinforcing sleeve 120. In some embodiments, reinforcing structure 122 is configured to allow tissue ingrowth to secure reinforcing sleeve 120 in place. In some embodiments, reinforcing sleeve 120 is not secured to lumen 110, but is simply secured by tissue ingrowth.


In some embodiments, the diameter of end caps 124 and 126 is slightly smaller than the outer diameter of lumen 110. Because the inner diameter of end caps 124 and 126 is slightly smaller than the outer diameter of lumen 110, reinforcing sleeve 120 is secured in the predetermined location. Further, because the inner diameter of end caps 124 and 126 is only slightly smaller than the outer diameter of lumen 110, flow through lumen 110 is only slightly affected or not impacted at all. In some embodiments, end caps 124 and 126 may include an enlarging ring 130. FIGS. 1 and 2 illustrate enlarging ring 130 placed inside the inner diameter of end cap 124, which enlarges the diameter of end cap 124 because enlarging ring 130 has a diameter slightly larger than the outer diameter of lumen 110 and larger than the natural diameter of end cap 124. Accordingly, the medical professional may slide reinforcing sleeve 120 to the predetermined location, and once reinforcing sleeve 120 is in the predetermined location, the medical professional may remove enlarging ring 130 by pulling on enlarging ring tab 132. Once enlarging ring 130 is removed, end cap 124 may restrict to its natural diameter, which is slightly smaller than the outer diameter of lumen 110, allowing end cap 124 to slightly grip lumen 110.


In some embodiments, medical device 100 may include multiple reinforcing sleeves 120 along lumen 110, as illustrated in FIG. 7. For example, if the flow path includes multiple locations that may be susceptible to crushing or tearing and where strength and/or crush resistance is warranted, multiple reinforcing sleeves 120 may be used in various locations along lumen 110 to reinforce lumen 110.



FIG. 8 illustrates medical device 100 implanted into a leg 12 of a patient 10. First end 112 of lumen 110 is coupled to the femoral artery 14 above the knee 16 of patient 10, while second end 114 of lumen 110 is coupled to femoral artery 14 below the knee 16 of patient 10, thereby bypassing a damaged portion of femoral artery 14. Reinforcing sleeve 120 is positioned along lumen 110 above the knee 16 of patient 10. Since the knee 16 undergoes a lot of movement, lumen 110 may be susceptible to damage. Accordingly, the medical professional may reinforce lumen 110 by adjusting the position of reinforcing sleeve 120. Additionally, more reinforcing sleeves 120 may be placed along lumen 110 to ensure that the flow path is protected. In other embodiments, medical device 100 is implanted at another location within patient 10, such as a foot, arm, or hand.



FIGS. 9-11 depict an embodiment of a medical device 200 that resembles medical device 100 described above in certain respects. Accordingly, like features are designated with like reference numerals, with the leading digits incremented to “2.” For example, the embodiment depicted in FIGS. 9-11 include a lumen 210 that may, in some respects, resemble the lumen 110 of FIGS. 1-7. Relevant disclosure set forth above regarding similarly identified features thus may not be repeated hereafter. Moreover, specific features of medical device 100 and related components shown in FIGS. 9-11 may not be shown or identified by a reference numeral in the drawings or specifically discussed in the written description that follows. However, such features may clearly be the same, or substantially the same, as features depicted in other embodiments and/or described with respect to such embodiments. Accordingly, the relevant descriptions of such features apply equally to the features of the medical device 200 and related components depicted in FIGS. 9-11. Any suitable combination of the features, and variations of the same, described with respect to the medical device 100 and related components illustrated in FIGS. 1-7 can be employed with the medical device 200 and related components of FIGS. 9-11, and vice versa. This pattern of disclosure applies equally to further embodiments depicted in subsequent figures and described hereafter, wherein the leading digits may be further incremented.



FIGS. 9-11 provide alternative views of medical device 200 (or a portion thereof) for improving blood flow to a region of a patient, such as a lower leg, a foot, an arm, or a hand. FIG. 9 illustrates medical device 200 with a lumen 210 and a reinforcing sleeve 220. Reinforcing sleeve 220 may include a reinforcing structure 222 that may be formed by winding (e.g., helically winding or coiling) a metal alloy. Reinforcing structure 222 may comprise and/or consist of a metal alloy that is inert in the human body. For example, in some embodiments, reinforcing structure 222 comprises and/or consists of a nickel-titanium alloy, such as nitinol. FIG. 10 illustrates a cross-sectional side view of medical device 200. Reinforcing structure 222 winds around lumen 210 to increase the crush resistance of lumen 210.


In some embodiments, similar to reinforcing sleeve 120, reinforcing sleeve 220 is configured to slide over lumen 210 and may be positioned to a predetermined location. In some embodiments, reinforcing sleeve 220 may be secured to lumen 210 by clamping, suturing, adhesive, and the like. In some embodiments, reinforcing sleeve 220 may be stretched and tightened on lumen 210 to secure reinforcing sleeve 220. In some embodiments, reinforcing sleeve 220 may be configured to allow tissue ingrowth to help secure reinforcing sleeve 220 in place. In some embodiments, reinforcing sleeve 220 is not secured to lumen 210 but is simply secured by tissue ingrowth. In other embodiments, end caps 224 and 226 (shown on FIG. 12) may have a slightly smaller diameter than the outer diameter of lumen 110.


The length of reinforcing sleeve 220 may be adjusted in a number of different ways. In some embodiments the length of reinforcing sleeve 220 may be adjusted by stretching reinforcing sleeve 220 to make reinforcing sleeve 220 longer. In some embodiments, reinforcing sleeve may be cut or trimmed by a cutting element 230 (scissors, scalpel, etc.), as illustrated in FIG. 11. The medical professional may remove a trimmed portion 223 to shorten the length of reinforcing structure 222 and reinforcing sleeve 220.


In some embodiments, as illustrated in FIG. 12, reinforcing sleeve 220 may further include end caps 224 and 226. End caps 224 and 226 may also provide a location for the medical professional to grip reinforcing sleeve 220 and to slide reinforcing sleeve 220 along lumen 210. As discussed previously, the medical professional may stretch reinforcing sleeve 220 by gripping end caps 224 and 226.


In some embodiments, end caps 224 and 226 may be attachable and detachable from reinforcing structure 222. For example, the medical professional may cut reinforcing structure 222 and remove end cap 224 attached to the trim portion 223 and replace end cap 224 on the uncapped end of reinforcing structure 222. End caps 224 and 226 may comprise an inert material in a human body, such as silicone, PTFE, etc.


In some embodiments, reinforcing sleeve 220 may be bent similar to reinforcing sleeve 120 illustrated in FIG. 4. Reinforcing sleeve 220 may bend up to at least 180 degrees and may prevent kinking of lumen 210. In addition, coiled reinforcing structure 222 may be as flexible as lumen 110.


In some embodiments, medical device 200 may include multiple reinforcing sleeves 220 along lumen 210. In some embodiments, medical device 200 may include different types of reinforcing sleeves, such as a reinforcing sleeve 120 with a braided reinforcing structure and a reinforcing sleeve 220 with a coiled reinforcing structure, as illustrated in FIG. 13. As each reinforcing sleeve 120 and 220 provides different benefits, the medical professional may decide to use reinforcing sleeve 120 in certain situations and reinforcing sleeve 220 in other situations.


In some embodiments, lumens 110 and 210 may be cannulated through reinforcing sleeves 120 and 220 as braided reinforcing structure 122 and coiled reinforcing structure 222 moves out of the way to enable the needle to pass through lumen 110.


In some embodiments, coiled reinforcing structure 222 may have a higher hoop force than braided reinforcing structure 122. In some embodiments, coiled reinforcing structure 222 may have a higher crush force than braided reinforcing structure 122.


The above disclosure has disclosed braided reinforcing structures 122 and wound reinforcing structures 222. However, the present disclosure is not so limited. Reinforcing sleeves may have a number of different structures to reinforce lumen 110, and it would be apparent to those having skill in the art that changes may be made to the structure of the reinforcing sleeves without departing from the underlying principles of the present disclosure.


Some embodiments relate to a kit for establishing a non-natural flow path within a patient. The kit may include, inter alia, the following components: a lumen 110, a plurality of reinforcing sleeves (e.g., 120, 220, etc.) with a variety of different reinforcing structures (122, 222, etc.) of varying length, cutting element 230, and instructions for creating a non-natural flow path within the patient. Cutting element 230 may be used to adjust the length of lumen 110, 210 or adjust the length of reinforcing sleeves 120 and 220.


In some embodiments, medical device 100, 200, etc., may be inserted into the patient (either percutaneously or through an “open” surgical procedure) and then coupled to the vasculature of the patient via anastomosis at the lateral ends of lumen 110.


Any methods disclosed herein include one or more steps or actions for performing the described method. The method steps and/or actions may be interchanged with one another. In other words, unless a specific order of steps or actions is required for proper operation of the embodiment, the order and/or use of specific steps and/or actions may be modified. Moreover, sub-routines or only a portion of a method described herein may be a separate method within the scope of this disclosure. Stated otherwise, some methods may include only a portion of the steps described in a more detailed method.


Reference throughout this specification to “an embodiment” or “the embodiment” means that a particular feature, structure, or characteristic described in connection with that embodiment is included in at least one embodiment. Thus, the quoted phrases, or variations thereof, as recited throughout this specification are not necessarily all referring to the same embodiment.


Similarly, it should be appreciated by one of skill in the art with the benefit of this disclosure that in the above description of embodiments, various features are sometimes grouped together in a single embodiment, figure, or description thereof for the purpose of streamlining the disclosure. This method of disclosure, however, is not to be interpreted as reflecting an intention that any claim requires more features than those expressly recited in that claim. Rather, as the following claims reflect, inventive aspects lie in a combination of fewer than all features of any single foregoing disclosed embodiment. Thus, the claims following this Detailed Description are hereby expressly incorporated into this Detailed Description, with each claim standing on its own as a separate embodiment. This disclosure includes all permutations of the independent claims with their dependent claims.


Recitation in the claims of the term “first” with respect to a feature or element does not necessarily imply the existence of a second or additional such feature or element. It will be apparent to those having skill in the art that changes may be made to the details of the above-described embodiments without departing from the underlying principles of the present disclosure.

Claims
  • 1. A method of reinforcing a non-natural flow path between a first portion of a vasculature and a second portion of the vasculature, the method comprising: obtaining a reinforcing sleeve that is configured to slide over a lumen;sliding the reinforcing sleeve along the lumen to a predetermined location; andsecuring the reinforcing sleeve to the lumen by removing an enlarging ring from between the lumen and an end cap of the reinforcing sleeve, such that the end cap comprises an inner diameter less than an outer diameter of the lumen.
  • 2. The method of claim 1, further comprising coupling a first end of the lumen to the first portion of the vasculature.
  • 3. The method of claim 2, further comprising coupling a second end of the lumen to the second portion of the vasculature.
  • 4. The method of claim 1, further comprising: providing a second reinforcing sleeve that is configured to slide over the lumen; andsliding the second reinforcing sleeve along the lumen to a second predetermined location.
  • 5. The method of claim 1, further comprising applying a push force to the reinforcing sleeve to slide the reinforcing sleeve along the lumen to the predetermined location.
  • 6. The method of claim 1, further comprising adjusting a length of the reinforcing sleeve.
  • 7. A non-natural flow path system between a first portion of a vasculature and a second portion of the vasculature, the system comprising: a lumen, wherein a first end of the lumen is configured to couple to the first portion of the vasculature and a second end of the lumen is configured to couple to the second portion of the vasculature; anda reinforcing sleeve configured to slide along the lumen to a predetermined position, the reinforcing sleeve comprising: an end cap disposed at an end of the reinforcing sleeve; andan enlarging ring removably disposed between the lumen and the end cap.
  • 8. The system of claim 7, wherein a crush force of the reinforcing sleeve is greater than a crush force of the lumen.
  • 9. The system of claim 7, wherein the reinforcing sleeve is bendable at least up to 180 degrees.
  • 10. The system of claim 7, wherein the reinforcing sleeve comprises a metal alloy.
  • 11. The system of claim 10, wherein the reinforcing sleeve is braided.
  • 12. The system of claim 10, wherein the reinforcing sleeve is helically wound.
  • 13. The system of claim 10, wherein the reinforcing sleeve opens when accessed with a needle.
  • 14. The system of claim 10, wherein the reinforcing sleeve further comprises a pair of end caps at opposing ends of the reinforcing sleeve.
  • 15. The system of claim 14, wherein the end caps are silicone.
  • 16. The system of claim 7, wherein the lumen comprises a layer that is an extruded elastomeric tube.
  • 17. The system of claim 7, wherein the lumen comprises porous PTFE.
  • 18. The system of claim 7, further comprising a second reinforcing sleeve.
  • 19. A non-natural flow path system between a first portion of a vasculature and a second portion of the vasculature, the system comprising: a lumen, wherein a first end of the lumen is configured to couple to the first portion of the vasculature, and a second end of the lumen is configured to couple to the second portion of the vasculature,wherein the lumen comprises a layer that is an extruded elastomeric tube; anda reinforcing sleeve configured to slide along the lumen to a predetermined position, the reinforcing sleeve comprising: an end cap disposed at an end of the reinforcing sleeve; andan enlarging ring removably disposed between the lumen and the end cap.
  • 20. The system of claim 19, wherein the layer self-seals.
RELATED APPLICATIONS

This application claims priority to U.S. Provisional Application No. 62/579,228, filed on Oct. 31, 2017 and titled, “SUBCUTANEOUS VASCULAR ASSEMBLIES FOR IMPROVING BLOOD FLOW AND RELATED DEVICES AND METHODS,” which is hereby incorporated by reference in its entirety.

US Referenced Citations (284)
Number Name Date Kind
3357432 Sparks Dec 1967 A
3435823 Edwards Apr 1969 A
3490438 Lavender et al. Jan 1970 A
3683926 Suzuki Aug 1972 A
3814137 Martinez Jun 1974 A
3818511 Goldberg et al. Jun 1974 A
3826257 Buselmeier Jul 1974 A
3853126 Schulte Dec 1974 A
3882862 Berend May 1975 A
3998222 Shihata Dec 1976 A
4076023 Martinez Feb 1978 A
4133312 Burd Jan 1979 A
4184489 Burd Jan 1980 A
4214586 Mericle Jul 1980 A
4318401 Zimmernan Mar 1982 A
4427219 Madej Jan 1984 A
4441215 Kaster Apr 1984 A
4447237 Frisch et al. May 1984 A
4496349 Cosentino Jan 1985 A
4496350 Cosentino Jan 1985 A
4503568 Madras Mar 1985 A
4550447 Seiler, Jr Nov 1985 A
4619641 Schanzer Oct 1986 A
4655771 Wallersten Apr 1987 A
4723948 Clark et al. Feb 1988 A
4734094 Jacob et al. Mar 1988 A
4743251 Barra May 1988 A
4753236 Healy Jun 1988 A
4771777 Horzewski et al. Sep 1988 A
4772268 Bates Sep 1988 A
4786345 Wood Nov 1988 A
4790826 Elftman Dec 1988 A
4822341 Colone Apr 1989 A
4848343 Wallsten et al. Jul 1989 A
4850999 Planck Jul 1989 A
4877661 House et al. Oct 1989 A
4898591 Jang et al. Feb 1990 A
4898669 Tesio Feb 1990 A
4917087 Walsh et al. Apr 1990 A
4919127 Pell Apr 1990 A
4929236 Sampson May 1990 A
4955899 Della Corna et al. Sep 1990 A
5026513 House et al. Jun 1991 A
5041098 Loiterman et al. Aug 1991 A
5053023 Martin Oct 1991 A
5061275 Wallsten et al. Oct 1991 A
5061276 Tu et al. Oct 1991 A
5064435 Porter Nov 1991 A
5084065 Weldon Jan 1992 A
5104402 Melbin Apr 1992 A
5171227 Twardowski et al. Dec 1992 A
5171305 Schickling et al. Dec 1992 A
5192289 Jessen Mar 1993 A
5192310 Herweck et al. Mar 1993 A
5197976 Herweck et al. Mar 1993 A
5282860 Matsuno et al. Feb 1994 A
5330500 Song Jul 1994 A
5336616 Livesey et al. Aug 1994 A
5399168 Wadsworth Mar 1995 A
5405320 Twardowski et al. Apr 1995 A
5405339 Kohnen et al. Apr 1995 A
5454790 Dubrul Oct 1995 A
5474268 Yu Dec 1995 A
5474563 Myler et al. Dec 1995 A
5476451 Ensminger et al. Dec 1995 A
5496294 Hergenrother et al. Mar 1996 A
5509897 Twardowski et al. Apr 1996 A
5549663 Cottone, Jr. Aug 1996 A
5558641 Glantz et al. Sep 1996 A
5562617 Finch, Jr. et al. Oct 1996 A
5562618 Cai et al. Oct 1996 A
5591226 Trerotola et al. Jan 1997 A
5607463 Schwartz et al. Mar 1997 A
5624413 Markel et al. Apr 1997 A
5637088 Wenner et al. Jun 1997 A
5637102 Tolkoff et al. Jun 1997 A
5645532 Horgan Jul 1997 A
5647855 Trooskin Jul 1997 A
5669637 Chitty et al. Sep 1997 A
5669881 Dunshee Sep 1997 A
5674272 Bush et al. Oct 1997 A
5676346 Leinsing Oct 1997 A
5743894 Swisher Apr 1998 A
5755773 Schuster May 1998 A
5755775 Trerotola et al. May 1998 A
5792104 Speckman et al. Aug 1998 A
5797879 Decampli Aug 1998 A
5800512 Lentz et al. Sep 1998 A
5800514 Nunez et al. Sep 1998 A
5800522 Campbell Sep 1998 A
5810870 Myers et al. Sep 1998 A
5830224 Cohn et al. Nov 1998 A
5840240 Stenoien et al. Nov 1998 A
5866217 Stenoien et al. Feb 1999 A
5904967 Ezaki et al. May 1999 A
5931829 Burbank et al. Aug 1999 A
5931865 Silverman et al. Aug 1999 A
5957974 Thompson et al. Sep 1999 A
5997562 Zadno-Azizi Dec 1999 A
6001125 Golds et al. Dec 1999 A
6019788 Butters et al. Feb 2000 A
6036724 Lentz et al. Mar 2000 A
6102884 Squitieri Aug 2000 A
6156016 Maginot Dec 2000 A
6167765 Weitzel Jan 2001 B1
6171295 Garabedian Jan 2001 B1
6231085 Olson May 2001 B1
6245098 Feeser Jun 2001 B1
6261255 Mullis et al. Jul 2001 B1
6261257 Uflacker et al. Jul 2001 B1
6280466 Kugler et al. Aug 2001 B1
6308992 Mitsui et al. Oct 2001 B1
6309411 Lashinski et al. Oct 2001 B1
6319279 Shannon et al. Nov 2001 B1
6338724 Dossa Jan 2002 B1
6398764 Finch, Jr. et al. Jun 2002 B1
6402767 Nash et al. Jun 2002 B1
6428571 Lentz et al. Aug 2002 B1
6436132 Patel et al. Aug 2002 B1
6582409 Squitieri Jun 2003 B1
6585762 Stanish Jul 2003 B1
6610004 Viole et al. Aug 2003 B2
6689096 Loubens et al. Feb 2004 B1
6689157 Madrid et al. Feb 2004 B2
6692461 Wantink Feb 2004 B2
6699233 Slanda et al. Mar 2004 B2
6702748 Nita et al. Mar 2004 B1
6702781 Reifart et al. Mar 2004 B1
6706025 Engelson et al. Mar 2004 B2
6719781 Kim Apr 2004 B1
6719783 Lentz et al. Apr 2004 B2
6730096 Basta May 2004 B2
6733459 Atsumi May 2004 B1
6740273 Lee May 2004 B2
6749574 O'Keefe Jun 2004 B2
6752826 Holloway et al. Jun 2004 B2
6758836 Zawacki Jul 2004 B2
6858019 McGuckin, Jr. et al. Feb 2005 B2
6926724 Chu Aug 2005 B1
6926735 Henderson Aug 2005 B2
6976952 Maini et al. Dec 2005 B1
6981987 Huxel et al. Jan 2006 B2
7011645 McGuckin, Jr. et al. Mar 2006 B2
7025741 Cull Apr 2006 B2
7044937 Kirwan et al. May 2006 B1
7101356 Miller Sep 2006 B2
7131959 Blatter Nov 2006 B2
7211074 Sansoucy May 2007 B2
7244271 Lenz et al. Jul 2007 B2
7244272 Dubson et al. Jul 2007 B2
7252649 Sherry Aug 2007 B2
7297158 Jensen Nov 2007 B2
7351257 Kaldany Apr 2008 B2
7399296 Poole et al. Jul 2008 B2
7438699 Pecor et al. Oct 2008 B2
7452374 Hain et al. Nov 2008 B2
7507229 Hewitt et al. Mar 2009 B2
7588551 Gertner Sep 2009 B2
7708722 Glenn May 2010 B2
7722665 Anwar et al. May 2010 B2
RE41448 Squitieri Jul 2010 E
7762977 Porter Jul 2010 B2
7789908 Sowinski et al. Sep 2010 B2
7828833 Haverkost et al. Nov 2010 B2
7833214 Wilson et al. Nov 2010 B2
7846139 Zinn et al. Dec 2010 B2
7850675 Bell et al. Dec 2010 B2
7850705 Bach et al. Dec 2010 B2
7922757 McGuckin, Jr. Apr 2011 B2
7972314 Bizup et al. Jul 2011 B2
8079973 Herrig Dec 2011 B2
8092435 Beling et al. Jan 2012 B2
8313524 Edwin et al. Nov 2012 B2
8388634 Rubenstein et al. Mar 2013 B2
8512312 Sage Aug 2013 B2
8551139 Surti et al. Oct 2013 B2
8690815 Porter et al. Apr 2014 B2
8951355 Clearflow et al. Feb 2015 B2
9642623 Agarwal et al. May 2017 B2
20010053930 Kugler et al. Dec 2001 A1
20020049403 Alanis Apr 2002 A1
20020055766 Wallace et al. May 2002 A1
20020055771 Sandock May 2002 A1
20020099432 Yee Jul 2002 A1
20020151761 Viole et al. Oct 2002 A1
20030100859 Henderson et al. May 2003 A1
20030135258 Andreas et al. Jul 2003 A1
20030135261 Kugler et al. Jul 2003 A1
20030139806 Haverkost et al. Jul 2003 A1
20030181969 Kugler et al. Sep 2003 A1
20030212385 Brenner et al. Nov 2003 A1
20030212431 Brady et al. Nov 2003 A1
20040024442 Sowinkski et al. Feb 2004 A1
20040054405 Thierry et al. Mar 2004 A1
20040073282 Stanish Apr 2004 A1
20040078071 Escamilla et al. Apr 2004 A1
20040147866 Blatter et al. Jul 2004 A1
20040193242 Lentz et al. Sep 2004 A1
20040215058 Zirps et al. Oct 2004 A1
20040215337 Hain et al. Oct 2004 A1
20040236412 Brar Nov 2004 A1
20050004553 Douk Jan 2005 A1
20050137614 Porter et al. Jun 2005 A1
20050192559 Michels et al. Sep 2005 A1
20050203457 Smego Sep 2005 A1
20050209581 Butts et al. Sep 2005 A1
20050215938 Khan et al. Sep 2005 A1
20060004392 Amarant Jan 2006 A1
20060029465 Auer Feb 2006 A1
20060058867 Thistle et al. Mar 2006 A1
20060064159 Porter et al. Mar 2006 A1
20060081260 Eells et al. Apr 2006 A1
20060118236 House et al. Jun 2006 A1
20070038288 Lye et al. Feb 2007 A1
20070078412 McGuckin, Jr. et al. Apr 2007 A1
20070078416 Eliasen Apr 2007 A1
20070078438 Okada Apr 2007 A1
20070088336 Dalton Apr 2007 A1
20070123811 Squitieri May 2007 A1
20070135775 Edoga et al. Jun 2007 A1
20070140797 Armstrong Jun 2007 A1
20070142850 Fowler Jun 2007 A1
20070161958 Glenn Jul 2007 A1
20070167901 Herrig et al. Jul 2007 A1
20070168019 Amplatz et al. Jul 2007 A1
20070173868 Bach et al. Jul 2007 A1
20070191779 Shubayev et al. Aug 2007 A1
20070197856 Gellman et al. Aug 2007 A1
20070213838 Hengelmolen Sep 2007 A1
20070219510 Zinn et al. Sep 2007 A1
20070233018 Bizup et al. Oct 2007 A1
20070244539 Lentz et al. Oct 2007 A1
20070249986 Smego Oct 2007 A1
20070249987 Gertner Oct 2007 A1
20070265584 Hickman et al. Nov 2007 A1
20070293823 Sherry Dec 2007 A1
20070293829 Conlon et al. Dec 2007 A1
20080009781 Anwar et al. Jan 2008 A1
20080027534 Edwin et al. Jan 2008 A1
20080132924 McGuckin Jun 2008 A1
20080167595 Porter et al. Jul 2008 A1
20080221469 Shevchuk Sep 2008 A1
20080306580 Jenson et al. Dec 2008 A1
20090076587 Cully Mar 2009 A1
20090137944 Haarala et al. May 2009 A1
20090179422 Werth Jul 2009 A1
20090227932 Herrig Sep 2009 A1
20090234267 Ross Sep 2009 A1
20090318895 Lachner Dec 2009 A1
20100154800 Chang et al. Jun 2010 A1
20100160718 Villafana et al. Jun 2010 A1
20100198079 Ross Aug 2010 A1
20100268188 Hanson Oct 2010 A1
20100268196 Hastings et al. Oct 2010 A1
20100292774 Shalev Nov 2010 A1
20110015723 Batiste et al. Jan 2011 A1
20110054312 Bell et al. Mar 2011 A1
20110060264 Porter et al. Mar 2011 A1
20110112482 Redd May 2011 A1
20110208218 Ball Aug 2011 A1
20110257609 Bizup et al. Oct 2011 A1
20110264080 Lim et al. Oct 2011 A1
20110295181 Dann et al. Dec 2011 A1
20120059305 Akingba Mar 2012 A1
20120065652 Cully et al. Mar 2012 A1
20120078202 Beling et al. Mar 2012 A1
20130060268 Herrig Mar 2013 A1
20130338559 Franano et al. Dec 2013 A1
20140018721 Gage et al. Jan 2014 A1
20140094841 Sutton et al. Apr 2014 A1
20140276215 Nelson Sep 2014 A1
20140288638 Knight et al. Sep 2014 A1
20140371779 Vale et al. Dec 2014 A1
20150051532 Tomko Feb 2015 A1
20150082604 Cully et al. Mar 2015 A1
20150094744 Aghayev Apr 2015 A1
20150150640 Boyle et al. Jun 2015 A1
20160066954 Miller et al. Mar 2016 A1
20160129177 Herrig May 2016 A1
20160279317 Gale Sep 2016 A1
20170020556 Sutton et al. Jan 2017 A1
20190015627 Hall et al. Jan 2019 A1
20190022368 Hall et al. Jan 2019 A1
20190184151 Herrig Jun 2019 A1
Foreign Referenced Citations (34)
Number Date Country
4418910 Dec 1995 DE
29515546 Mar 1997 DE
102008055587 Aug 2009 DE
1797831 Jun 2007 EP
62112567 May 1987 JP
04507050 Dec 1992 JP
05212107 Aug 1993 JP
06105798 Apr 1994 JP
09084871 Mar 1997 JP
09264468 Jul 1997 JP
2003501223 Jan 2003 JP
3995057 Oct 2007 JP
2008511414 Apr 2008 JP
101026933 Apr 2011 KR
1020110036848 Apr 2011 KR
198403036 Aug 1984 WO
199008509 Aug 1990 WO
199519200 Jul 1995 WO
199624399 Aug 1996 WO
1998034676 Aug 1998 WO
2000027299 May 2000 WO
200076577 Dec 2000 WO
200105447 Jan 2001 WO
200105463 Jan 2001 WO
2001028456 Apr 2001 WO
2004032991 Apr 2004 WO
2004112880 Dec 2004 WO
2006026687 Sep 2006 WO
2009059371 May 2009 WO
2010059102 May 2010 WO
2011060386 May 2011 WO
2011153302 Dec 2011 WO
2012143922 Oct 2012 WO
2015100251 Jul 2015 WO
Non-Patent Literature Citations (63)
Entry
Notice of Allowance dated Mar. 11, 2020 for U.S. Appl. No. 15/828,040.
Office Action dated Oct. 17, 2019 for U.S. Appl. No. 15/828,040.
Office Action dated Apr. 28, 2020 for U.S. Appl. No. 14/192,567.
Office Action dated May 1, 2020 for U.S. Appl. No. 15/693,010.
International Search Report and Written Opinion dated Apr. 4, 2019 for PCT/US2018/058179.
Office Action dated Aug. 21, 2019 for U.S. Appl. No. 14/192,567.
Office Action dated Sep. 26, 2019 for U.S. Appl. No. 15/693,010.
Lin, et al., Contemporary Vascular Access Surgery for Chronic Haemodialysis, They Royal College of Surgeons of Edinburgh, J.R. Coll, Surg, Edinb., 41 ,Jun. 1996 ,164-169.
Peterson, et al., Subclavian Venous Stenosis: A Complication of Subclavian Dialysis, The Journal of American Medical Association, vol. 252 No. 24 ,Dec. 28, 1994 ,3404-3406.
Raju M.D., et al., Techniques for Insertion and Management of Complications, PTFE Grafts for Hemodialysis Access, Ann. Surg., vol. 206 No. 5 ,Nov. 1987 ,666-673.
Sharafuddin, et al., Percutaneous Balloon-Assisted Aspiration Thrombectomy of clotted ahemodialysis Access Grafts, Journal of Vascular and Interventional Radiology, vol. 7 No. 2 ,Mar.-Apr. 1996, 177-183.
European Search Report dated Jun. 8, 2005 for EP05006233.0.
European Search Report dated Dec. 3, 2013 for EP05793066.1.
International Preliminary Report dated Mar. 12, 2014 for PCT/US2012/053967.
International Search Report and Written Opinion dated Jan. 18, 2019 for PCT/US2018/041821.
International Search Report and Written Opinion dated Jan. 28, 2015 for PCT/US2014/049547.
International Search Report and Written Opinion dated Mar. 15, 2013 for PCT/US2012/053967.
International Search Report and Written Opinion dated Mar. 16, 2015 for PCT/US2014/046630.
International Search Report and Written Opinion dated May 2, 2018 for PCT/US2018/013326.
International Search Report and Written Opinion dated May 3, 2013 for PCT/US2012/053967.
International Search Report and Written Opinion dated May 6, 1998 for PCT/US1998/001939.
International Search Report and Written Opinion dated Jun. 3, 2009 for PCT/US2009/035923.
International Search Report and Written Opinion dated Jun. 15, 2018 for PCT/US2018/020614.
International Search Report and Written Opinion dated Jun. 20, 2007 for PCT/US2006/044564.
International Search Report and Written Opinion dated Jul. 17, 2018 for PCT/US2018/023956.
International Search Report and Written Opinion dated Oct. 30, 2018 for PCT/US2018/042900.
International Search Report and Written Opinion dated Jun. 22, 2018 for PCT/US2018/014371.
Notice of Allowance dated Mar. 15, 2010 for U.S. Appl. No. 11/216,536.
Notice of Allowance dated Oct. 4, 2013 for U.S. Appl. No. 12/831,092.
Notice of Allowance dated Oct. 5, 2018 for U.S. Appl. No. 15/093,622.
Notice of Allowance dated Nov. 6, 2018 for U.S. Appl. No. 14/995,270.
Office Action dated Jan. 8, 2019 for U.S. Appl. No. 15/035,626.
Office Action dated Jan. 9, 2018 for U.S. Appl. No. 14/450,468.
Office Action dated Feb. 6, 2013 for U.S. Appl. No. 12/831,092.
Office Action dated Feb. 21, 2017 for U.S. Appl. No. 14/192,567.
Office Action dated Mar. 15, 2018 for U.S. Appl. No. 14/332,091.
Office Action dated May 5, 2010 for U.S. Appl. No. 10/962,200.
Office Action dated May 24, 2018 for U.S. Appl. No. 14/995,270.
Office Action dated Jun. 4, 2018 for U.S. Appl. No. 14/192,567.
Office Action dated Jun. 9, 2016 for U.S. Appl. No. 14/192,567.
Office Action dated Jun. 15, 2017 for U.S. Appl. No. 14/192,567.
Office Action dated Jul. 11, 2018 for U.S. Appl. No. 14/450,468.
Office Action dated Jul. 19, 2018 for U.S. Appl. No. 15/035,626.
Office Action dated Aug. 7, 2017 for U.S. Appl. No. 14/450,468.
Office Action dated Aug. 12, 2010 for U.S. Appl. No. 10/962,200.
Office Action dated Aug. 15, 2016 for U.S. Appl. No. 14/332,091.
Office Action dated Sep. 20, 2012 for U.S. Appl. No. 12/831,092.
Office Action dated Oct. 1, 2018 for U.S. Appl. No. 14/332,091.
Office Action dated Oct. 27, 2015 for U.S. Appl. No. 14/192,567.
Office Action dated Nov. 26, 2007 for U.S. Appl. No. 10/962,200.
Office Action dated Dec. 5, 2017 for U.S. Appl. No. 14/995,270.
Office Action dated Dec. 5, 2018 for U.S. Appl. No. 14/450,468.
Office Action dated Dec. 7, 2018 for U.S. Appl. No. 14/192,567.
Office Action dated Dec. 20, 2017 for U.S. Appl. No. 14/192,567.
Office Action dated Dec. 30, 2016 for U.S. Appl. No. 14/450,468.
Clinical Reveiw of MTI, Onxy Liquid Embolization System, available at http://www.fda.gov/ohrms/dockets/ac/03/briefing/3975b1-02-clinical-review.pdf. accessed Aug. 29, 2005.
Besarab, et al., Measuring the Adequacy of Hemodialysis Access, Current Opinion in Nephrology and Hypertension, Rapid Science Publishers ISSN ,1996 ,1062-4821.
Coulson MD, et al., Modification of Venous End of Dialysis Grafts: An Attempt to Reduce Neointimal Hyperplasia, Dialysis & Transplantation, vol. 29 No. Jan. 1, 2000 ,10-18.
Coulson MD, PHD, et al., A Combination of the Elephant Trunk Anastomosis Technique and Vascular Clips for Dialysis Grafts, Surgical Rounds ,Nov. 1999 ,596-608.
Kanterman, et al., Dialysis Access Grafts: Anatomic Location of Venous Stenosis and Results of Angioplasty, Interventional Radiology, vol. 195 No. 1, 195 ,Apr. 1995 ,135-139.
Kumpe, et al., Angioplasty/Thrombolytic Treatment of Failing and Failed Hemodialysis Access Sites: Comparison with Surgical Treatment, Progress in Cardiovascular Diseases, vol. XXXIV No. 4 ,Jan./Feb. 1992 ,263-278.
Office Action dated Apr. 6, 2021 for U.S. Appl. No. 16/284,526.
European Search Report dated Jul. 8, 2021 for EP18874078.1.
Related Publications (1)
Number Date Country
20190126017 A1 May 2019 US
Provisional Applications (1)
Number Date Country
62579228 Oct 2017 US